Inhibikase Therapeutics, Inc.
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$1.94
FAIR PRICE
$2.31
MARGIN
$0.38
P/E Ratio
N/A
Div. Yield
N/A
ROE
-46.9%
Average
Market Cap
$132M
Small-cap
NOW AVAILABLE
Get notified when IKT's fair price changes
Push notifications when IKT's valuation shifts. Available on iOS and Android.
FPI RATING
Strong profitability and attractive valuation, but volatile earnings pattern and limited growth momentum.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$1.85
Fair price × 0.80
DISTANCE
4.5%
Price to entry level
At the current price of $1.94, IKT trades 4.5% above the conservative entry level of $1.85. This entry level represents a 20% margin of safety below the calculated fair price of $2.31 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
P/E RATIO HISTORY
Loading chart data...
METHODOLOGY
How we calculate IKT's fair price
Inhibikase Therapeutics, Inc.'s fair price of $2.31 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $1.94, IKT trades 19.4% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting IKT's risk profile.
RELATIVE · 30%
Comparing IKT's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for IKT, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate IKT's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for IKT.
Explore on BuliosFAQ
What is the fair price of IKT?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Inhibikase Therapeutics, Inc. is $2.31. At the current market price of $1.94, IKT trades 19.4% below its calculated fair value.
Is IKT overvalued or undervalued?+
Inhibikase Therapeutics, Inc. is currently undervalued based on our valuation model. The stock trades at $1.94, which is 19.4% below the fair price of $2.31.
What is the margin of safety for IKT?+
With a 20% margin of safety applied to the fair price of $2.31, the conservative entry level for IKT is $1.85. At the current market price of $1.94, the stock trades 4.5% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is IKT's fair price updated?+
We update fair price calculations for IKT daily after market close. The current fair price of $2.31 incorporates the latest market data and sector multiples.
What factors affect IKT's fair price calculation?+
IKT's fair price of $2.31 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -46.9%.
Is IKT a good buy right now?+
At $1.94, IKT trades 19.4% below our fair value estimate of $2.31. The stock is currently undervalued. ROE stands at -46.9% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does IKT pay dividends?+
IKT does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.